Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marko Tomov

Orthopaedic Surgery of the Spine Casper, WY Medical Doctor

NPI 1902221898 CMS profile 4221026

4140 Centennial Hills Blvd Ste A, Ste C, Casper, WY 82609

Open in the dashboard

General payments

$18,396

115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marko Tomov of Casper, WY is reported in the CMS Open Payments database as having received $18,396 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,916 20
2024 General $4,655 19
2023 General $3,839 15
2022 General $3,219 30
2021 General $1,424 11
2020 General $229 4
2019 General $2,114 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marko Tomov
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Marko Tomov were reported at $2,916. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Marko Tomov Orthopaedic Surgery of the Spine median Middle half National median
2019 $2,114 $2,106 $337–$18,608 $163
2020 $229 $1,213 $156–$15,082 $114
2021 $1,424 $1,834 $271–$15,617 $132
2022 $3,219 $2,015 $320–$17,036 $149
2023 $3,839 $1,925 $336–$14,599 $160
2024 $4,655 $2,110 $341–$12,483 $164
2025 $2,916 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $6,471 50 payments
  2. Alphatec Spine, Inc $4,440 10 payments
  3. OsteoCentric Technologies, Inc. $2,528 9 payments
  4. Medical Device Business Services, Inc. $1,817 13 payments
  5. Stryker Corporation $763 6 payments
  6. Arthrex, Inc. $360 3 payments
  7. Gemini Mountain Medical, LLC $360 1 payment
  8. NuVasive, Inc. $355 4 payments
  9. Sawtooth Surgical Solutions Inc $233 4 payments
  10. DePuy Synthes Sales Inc. $213 3 payments
  11. Other $857 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $8,931 25 payments
  2. Food and Beverage $6,038 82 payments
  3. Consulting Fee $2,000 1 payment
  4. Education $1,426 7 payments
Products named General payments · program years 2019–2025
  1. Other - Miscellaneous $3,966 6 payments
  2. PIVOX Oblique Lateral Spinal System $2,774 16 payments
  3. OsteoCentric 4.0 x 130mm LOCKING BONE SCREW FASTENER ST $2,528 9 payments
  4. ACTIS $1,497 11 payments
  5. ATTUNE $1,497 11 payments
  6. CLYDESDALE PTC SPINAL SYSTEM $614 2 payments
  7. Mazor X Stealth Edition $547 2 payments
  8. UNID_PASS $521 7 payments
  9. ANTERALIGN SPINAL SYSTEM WITH TITAN NANOLOCK SURFACE TECHNOLOGY $468 4 payments
  10. PRESTIGE LP CERVICAL DISC SYSTEM $350 1 payment
  11. Other $4,312 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

340

Median for Orthopedic Surgery: 203

Drug cost

$2,048

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 203 $734
Gabapentin Generic 71 $665
Methocarbamol Generic 35 $409
Methylprednisolone Generic 31 $239

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$104,424

Medicare's payments for the services billed

Medicare patients

332

Average age 73

Services billed

815

191 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Diabetes 23%
Ischemic heart disease 22%
Depression 21%
Osteoporosis 21%
Chronic kidney disease 19%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record